07:00 , May 31, 2010 |  BC Week In Review  |  Company News

AndroScience, Orient deal

AndroScience granted Orient exclusive rights in Taiwan, Hong Kong, South Korea, New Zealand, Australia and other Asia Pacific territories to commercialize ASC-J9. Orient will fund a Phase IIb trial of the topical anti-androgen that...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Androgen receptor ...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

ASC-J9: Phase IIa data

Data from a double-blind, U.S. Phase IIa trial in 186 patients showed that 0.025% topical ASC-J9 twice daily reduced inflammatory lesions at 12 weeks vs. vehicle. The study was not powered for significance. AndroScience Corp.,...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Clinical News

ASC-J9: Phase I start

This quarter, AndroScience will begin an open-label, U.S. Phase I trial in 28 patients. AndroScience Corp., San Diego, Calif.   Product: ASC-J9   Business: Dermatology   Molecular target: NA   Description: Topical anti-androgen that enhances androgen receptor...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Clinical News

ASC-J9: Phase I start

This quarter, AndroScience will begin a double-blind, U.S. Phase I trial in 24 healthy volunteers. AndroScience Corp., San Diego, Calif.   Product: ASC-J9   Business: Dermatology   Molecular target: NA   Description: Topical anti-androgen that enhances androgen...